Abstract Rationale: The atypical antipsychotic drug (APD) clozapine (CLZ) has been shown to have a robust discriminative cue in rats, pigeons, and monkeys in twochoice drug discrimination procedures. Objectives: The present study determined whether a two-choice drug discrimination procedure with CLZ could be established in C57BL/6 mice and whether this procedure could distinguish between atypical and typical APDs. Methods: C57BL/6 male mice were trained to discriminate 2.5 mg/kg CLZ from vehicle in a two-lever drug discrimination procedure. Results: Generalization testing with CLZ produced full substitution at the 2.5-and 5.0-mg/kg doses with an ED 50 of 1.14 mg/kg. The atypical APDs olanzapine (ED 50 =0.24 mg/ kg), risperidone (ED 50 =0.072 mg/kg), and ziprasidone (ED 50 =0.33 mg/kg) fully substituted for CLZ's discriminative cue, while the typical APD haloperidol failed to substitute for CLZ. Generalization testing with selective ligands showed that the serotonin (5-HT) 2A/2B/2C antagonist ritanserin fully substituted for CLZ (ED 50 =2.08 mg/ kg) and that the 5-HT receptor agonist quipazine significantly attenuated CLZ's discriminative cue without disrupting response rates. The muscarinic receptor antagonist scopolamine, the dopamine agonist amphetamine, and the 5-HT agonist quipazine failed to substitute for CLZ. Conclusions: These results demonstrated that antagonism of 5-HT receptors plays an important role in mediating the discriminative stimulus properties of the atypical APD CLZ in C57BL/6 mice. The atypical APDs olanzapine, risperidone, and ziprasidone fully substituted for CLZ, while the typical APD haloperidol did not. These results suggest that CLZ drug discrimination in C57BL/6 mice may be an effective preclinical behavioral assay for screening atypical from typical antipsychotic drugs.
Introduction
The atypical antipsychotic drug (APD) clozapine (CLZ) displays a preferentially high binding affinity for serotonin 2A (5-HT 2A ) over dopamine (DA) D 2 receptors, as is consistent with the 5-HT/DA hypothesis for atypical APD efficacy (Meltzer et al. 1989 (Meltzer et al. , 2003 . Meltzer et al. (1989 Meltzer et al. ( , 2003 have argued that potent 5-HT 2A antagonism combined with relatively weaker DA D 2 antagonism represents the principal pharmacological mechanism of action that distinguishes CLZ and other atypical APDs (e.g., olanzapine, risperidone, and ziprasidone) from typical APDs (e.g., haloperidol), although it should be noted that other theories such as the "fast-off D 2 " theory have been proposed as possible explanations for the atypical characteristics of the atypical APDs (Seeman 2002) . Thus, development of preclinical assays that target 5-HT mechanisms (as well as DA) represents an important goal for the development of new atypical or novel APDs with improved efficacy and reduced side effects.
Drug discrimination is an important behavioral assay that has been used to classify drugs in terms of their subjective effects and to identify underlying mechanisms of pharmacological action in vivo. CLZ has been established as a discriminative stimulus in several species including rats (e.g., Goas and Boston 1978; Wiley and Porter 1992; Prus et al. 2004) , monkeys , and pigeons (Hoenicke et al. 1992) , and the CLZ drug discrimination paradigm has proven useful for screening a number of putative atypical APDs preclinically (Bruhwyler et al. 1997; Tang et al. 1997; Millan et al. 1998 Millan et al. , 1999 Millan et al. , 2000 . CLZ appears to elicit a discriminative cue with multiple stimulus effects, but the specific pharmacological mechanisms mediating the CLZ cue have yet to be determined.
CLZ displays a diverse receptor binding profile that has a high affinity for a variety of receptors including 5-HT, muscarinic, histaminergic, and adrenergic receptors (Schotte et al. 1996) . Muscarinic antagonists, including scopolamine and trihexyphenidyl, are the only receptor-selective ligands that reliably substitute for the CLZ discriminative cue in rats (Nielsen 1988; Kelley and Porter 1997; Prus et al. 2004 ). Yet, 5-HT 2A/2B/2C receptor antagonists, such as ritanserin (Wiley and Porter 1992) and M100907 Millan et al. 1999; Prus et al. 2004 ), fail to substitute for the CLZ discriminative cue. In addition, histamine and noradrenalin receptor antagonists also fail to substitute for CLZ. These findings have led to the suggestion that the discriminative stimulus properties of CLZ in rats are mediated by muscarinic receptor antagonism (Kelley and Porter 1997; Goudie and Smith 1999) . This hypothesis may account for the inability of the atypical APDs, risperidone (Hoenicke et al. 1992; Fiorella et al. 1997; although cf. Porter et al. 2000) and ziprasidone (Millan et al. 1999) , which are weak muscarinic receptor antagonists and potent 5-HT antagonists, to substitute for CLZ; while olanzapine, which displays a high muscarinic receptor affinity, produces full generalization to the CLZ cue (Moore et al. 1992; Millan et al. 1999; Porter et al. 2000) . CLZ and the muscarinic antagonist scopolamine also fully substitute for the atypical APD quetiapine, while 5-HT antagonists do not (Goudie et al. 2004 ). However, it should be noted that the atypical APD and weak muscarinic receptor antagonist melperone has been shown to produce full substitution for CLZ in rats (Prus et al. 2004) , while the typical APD and potent muscarinic receptor antagonist chlorpromazine fails to substitute for CLZ (Goas and Boston 1978; Porter et al. 2004) . Thus, while muscarinic receptor antagonism is shared by some atypical APDs, this mechanism does not appear to be sufficient to explain substitution or lack of substitution by atypical and typical APDs. Dekeyne et al. (2003) recently established the selective 5-HT 2A receptor antagonist MDL100,907 as a discriminative stimulus in rats and reported full substitution by the atypical APDs CLZ, quetiapine, risperidone, and ziprasidone and also by the typical APD haloperidol. Thus, further efforts are needed to improve CLZ drug discrimination as a preclinical screening model for atypical APDs in rats.
While the majority of CLZ drug discrimination research has been conducted using rats, some studies have featured pigeons and monkeys and have, at times, yielded different results. Hoenicke et al. (1992) trained pigeons to discriminate CLZ and found that the 5-HT 2A/2C antagonist pizotifen, but not ketanserin, produced full substitution for CLZ, while the muscarinic antagonist scopolamine failed to substitute for CLZ. Both the atypical APD risperidone and the typical APD haloperidol also failed to substitute for CLZ in pigeons. In rats trained to discriminate a 5.0-mg/kg dose of CLZ, full substitution for CLZ occurs with scopolamine, but not with ritanserin, or risperidone, thus providing some inconsistent results across species (Wiley and Porter 1992; Kelley and Porter 1997) . In monkeys, the atypical APD quetiapine produced full substitution for a CLZ discriminative cue, yet the atypical APDs olanzapine, risperidone, and remoxipride did not; however, it should be noted that olanzapine produced full substitution for CLZ when its rate-suppressing effects were blocked by coadministration of the DA D 2 agonist (+)-PHNO . In rats, risperidone and quetiapine have produced full substitution for a 1.25-mg/kg (Porter et al. 2000 ) and a 5.0-mg/kg CLZ Millan et al. 1999 ) training dose, respectively, while olanzapine has produced full substitution for both of these training doses (Moore et al. 1992; Millan et al. 1999; Porter et al. 2000 Porter et al. , 2004 although, cf. Goudie et al. 1998) . Thus, there appear to be differences in the discriminative stimulus properties of CLZ across species, although it should be noted that methodological differences also may account for some of these discrepancies.
Recent drug discrimination investigations using C57BL/6 mice have shown that the 5-HT 2A receptor agonist DOI can be established as a discriminative stimulus in mice and that 5-HT 2A receptor antagonists block the DOI discriminative cue. The dose required to establish DOI as a discriminative stimulus in C57BL/6J mice (Smith et al. 2003) was four times higher than the dose used in rats (Glennon 1986 ), suggesting possible differences in the 5-HT-mediated stimulus effects of DOI between rats and mice. C57BL/6 mice also have been shown to be less sensitive to the effects of the muscarinic antagonist scopolamine as compared to DBA mice in a delayed matching-to-sample task (Estape and Steckler 2002) . Given the evidence that the discriminative stimulus properties of CLZ can differ between species and that mice appear to respond differentially to 5-HT and muscarinic receptor-mediated effects (as compared to rats), the goals of the present study were: (1) to establish a twolever CLZ drug discrimination procedure using C57BL/6 mice; (2) to test the atypical APDs olanzapine, risperidone, and ziprasidone and the typical APD haloperidol; and (3) to test selective serotonergic, dopaminergic, and muscarinic ligands to determine the pharmacological basis of the discriminative stimulus properties of CLZ in C57BL/6 mice.
Materials and methods

Animals
Twenty male C57BL/6 wild-type mice weighing 20-25 g (Harlan Laboratories, Indianapolis, IN) were used as subjects. All research was conducted in accordance with the Guide for the Care and Use of Laboratory Animals (National Research Council, 2003) , and all procedures were approved by the Institutional Animal Care and Use Committee at Virginia Commonwealth University. The mice were food-restricted to 90-95% of their free-feeding body weights. Water was available ad libitum in the home cages, and the mice were housed individually in a temperature-controlled vivarium under a 12-h light/dark cycle (0600/1800 h).
Apparatus
Drug discrimination experiments were conducted in five standard computer-interfaced mouse operant conditioning chambers (Model ENV-307A; Med Associates, St. Albans, VT) with two retractable levers positioned equidistantly from a liquid dipper. Experimental events and data collection during these experiments were controlled by Med-PC for Windows software (Med Associates).
Drugs
Clozapine (gift from Novartis, Hanover, NJ), haloperidol (Sigma, St. Louis, MO), olanzapine (gift from Eli Lilly, Indianapolis, IN), ritanserin (Research Biochemicals International, Natick, MS), and ziprasidone (ziprasidone mesylate, Roerig, Division of Pfizer, New York, NY) were dissolved in distilled water with a few drops of lactic acid. Scopolamine, quipazine, and amphetamine (Sigma) were dissolved in distilled water. All drugs were administered subcutaneously (s.c.) at a volume of 10 ml/kg body weight 60 min prior to test sessions. All doses refer to the salt form of the drugs.
Procedure
Training Mice were initially trained to lever press under a fixed ratio 1 (FR 1) schedule for liquid food reinforcers (0.02 ml of sweetened-condensed milk, by volume: one part condensed milk, one part sugar, and three parts water) during daily 15-min sessions. The FR requirement was gradually increased until responding occurred under an FR 10 reinforcement schedule. Initially, a 5.0-mg/kg CLZ training dose was used, but this dose was abandoned due to severe rate suppressant effects that persisted for several weeks. A 2.5-mg/kg dose of CLZ was subsequently used as the training dose. Prior to each training session, mice received either a 2.5-mg/kg CLZ or vehicle (VEH) injection according to a double alternation sequence (i.e., CLZ, CLZ, VEH, VEH, CLZ, CLZ, etc.), and only responses on the condition appropriate lever were reinforced. A response on the incorrect lever reset the FR counter to 10. The position of the CLZ-appropriate lever (left vs right) was counterbalanced between groups to control for olfactory cues (Extance and Goudie 1981) . The discrimination training criteria for all subjects consisted of (1) completing the first FR on the correct lever, (2) at least 10 responses per minute (RPM), and (3) at least 80% condition-appropriate responding for five out of six consecutive training sessions.
Testing Before generalization testing began, subjects had to meet training criteria. Subsequently, these criteria had to be met for at least two training sessions between each drug test session. Moreover, control tests with the training drug CLZ (2.5 mg/kg) and VEH had to be successfully completed prior to testing each drug. Drug test sessions differed from training sessions in that FR 10 responding on either lever resulted in delivery of reinforcers (responses on one lever still reset the FR 10 response requirement on the other lever).
Data analysis The number of lever presses on each lever during test sessions was recorded for each mouse and converted into percent drug-lever responding (% DLR) and response rate. Response rate was calculated as the mean responses per minute (RPM) for each session. Percent druglever responding was not included in the dose-response curves for mice that failed to obtain a reinforcer or if response rate fell below 2 RPM. ED 50 values (using the leastsquares method of linear regression on the linear portion of the curves) and 95% confidence intervals (CI) were calculated for the % DLR generalization curves in which at least one drug dose generated 80% or more CLZ-appropriate responding. Full generalization to the CLZ cue was defined as 80% or greater CLZ-appropriate responding, while partial generalization was defined as CLZ-appropriate responding ≥60 and <80%. A repeated-measures analysis of variance (ANOVA) was conducted on response rate data to assess significant effects of drug doses on response rates and to analyze differences in % DLR for the CLZ time course (GB-STAT software; Dynamic Microsystems, Silver Spring, MD). Significant ANOVAs were followed by Newman-Keuls post-hoc tests (p<0.05).
Results
Clozapine generalization testing
Sixteen of the 20 mice initially met the training criteria in an average of 35.6 sessions (SEM±2.84; range=15-52 sessions); however, three mice were removed from the study prior to the CLZ generalization curve because of unreliable performance during continued training sessions. The mean % DLR (±SEM) and the mean RPM (±SEM) for the CLZ generalization curve are shown in Fig. 1 . Full generalization to the CLZ cue was obtained at the 2.5-mg/kg training dose and at 5.0 mg/kg (ED 50 =1.14 mg/kg; 95% CI=0.96-1.34 mg/kg). While there was a significant increase in responding (relative to VEH) at the 1.25-mg/kg dose of CLZ, there was significant rate suppression (F 7,84 =35.203, p<0.0001) observed at the 5.0-mg/kg dose (only four out of 13 mice had response rates equal to or greater than 2 RPM and were included in the % DLR data).
Clozapine time course
Time course data (% DLR) shown in the upper panel of Fig. 2 revealed that the 2.5-mg/kg training dose of CLZ produced full generalization to the CLZ cue (≥80% DLR) from 15 up to 60 min after s.c. injection. The level of CLZ-appropriate responding decreased significantly (relative to the 60-min training injection time) to an average of 55.9% at 0 min, 48.4% after 120 min, and 24.3% after 240 min postinjection (F 5,40 =14.046, p<0.0001). Rates of responding remained stable over the entire time course. The lower panel of Fig. 1 shows the percent of mice completing the first fixed ratio (FFR) on the CLZ lever. Again, full generalization (defined as 80% or more of the mice completing the FFR on the CLZ lever) was seen at the 15-, 30-, and 60-min injection times with significant decreases (relative to 60 min) at 0, 120, and 240 min (F 5,40 =8.957, p<0.0001). Fig. 2 Results for the % DLR data for the clozapine time course study are shown in the upper panel. In the lower panel, the percent of mice completing the first fixed ratio (FFR) on the CLZ lever are shown. Significant differences from the 60-min presession injection time are indicated by asterisks (*p<0.05; **p<0.01). See Fig. 1 for other details Fig. 3 Generalization testing with the atypical antipsychotic drugs olanzapine (upper panel), risperidone (middle panel), and ziprasidone (bottom panel) are shown for C57BL/6 mice trained to discriminate 2.5 mg/kg clozapine from vehicle. See Fig. 1 for other details Fig. 1 The mean percent drug lever responding (% DLR) and mean responses per minute (RPM) for the clozapine generalization curve in C57BL/6 mice trained to discriminate 2.5 mg/kg clozapine (CLZ) from vehicle (VEH) are shown. The dashed line at 80% DLR indicates full generalization to CLZ. Prior to generalization testing, control tests were conducted with the CLZ training dose and VEH. Mice that failed to earn a reinforcer or with response rates below 2 RPM were not included in the % DLR data (number of mice included is shown in parentheses). For the response rate data, significant differences from VEH are indicated by asterisks (*p<0.05; **p<0.01) Olanzapine, risperidone, and ziprasidone generalization testing
The results of generalization testing for the atypical APDs olanzapine (upper panel), risperidone (middle panel), and ziprasidone (lower panel) are presented in Fig. 3 . Olanzapine produced full substitution for CLZ at the 1.0-mg/kg (87.3% DLR) and 2.0-mg/kg (86.7% DLR) doses with an ED 50 of 0.24 mg/kg (95% CI=0.18-0.32 mg/kg). Response rates were significantly increased by the 0.125-, 0.25-, and 0.5-mg/kg doses of olanzapine (as compared to VEH) but were significantly reduced by the 2.0-mg/kg dose (F 7, 77 =31.126, p<0.0001). Risperidone (Fig. 3 , middle panel) also fully substituted for CLZ at two doses with 86.1% DLR at 0.25 mg/kg and 95.0% DLR at 0.50 mg/ kg. The ED 50 for risperidone was 0.072 mg/kg (95% CI=0.045-0.116 mg/kg). There were significant decreases in response rates relative to VEH at the 0.125-, 0.25-, and 0.5-mg/kg doses of risperidone (F 5,30 =6.433, p<0.0001). Ziprasidone (Fig. 3 , bottom panel) produced full substitution for CLZ at the 1.0-mg/kg (83.3% DLR) and 2.0-mg/kg (93.6% DLR) doses. Significant rate suppression was observed when compared to VEH at the 1.0-and 2.0-mg/kg doses of ziprasidone (F 5,35 =17.297, p<0.0001).
Haloperidol and amphetamine generalization testing Figure 4 shows the results of generalization testing for the typical APD and DA D 2 receptor antagonist haloperidol (upper panel) and for the DA agonist amphetamine (lower panel). The typical APD haloperidol did not substitute for CLZ, producing a maximum of 51.6% DLR at the 0.2-mg/ kg dose of haloperidol. The 0.4-mg/kg dose of haloperidol produced a significant decrease in response rates as compared to VEH (F 5,50 =38.781, p<0.0001). The DA agonist amphetamine also failed to substitute for CLZ, producing a maximum of 8.1% DLR at 0.25 mg/kg. Relative to vehicle responding, response rates were significantly decreased by the 1.0-mg/kg dose of amphetamine (F 4,32 =9.833, p<0.0001).
Ritanserin and scopolamine generalization testing
Results for generalization testing with the 5-HT 2A/2B/2C receptor antagonist ritanserin and muscarinic cholinergic antagonist scopolamine are shown in Fig. 5 . The 5-HT antagonist ritanserin (upper panel) fully substituted for CLZ at the 8.0-mg/kg dose (94.5% DLR), producing an ED 50 of 2.08 mg/kg (95% CI=1.42-3.06 mg/kg). Ritanserin pro- duced a significant suppression in response rates (as compared to VEH) at 4.0 and 8.0 mg/kg (F 5,35 =5.089, p<0.005). In contrast, the muscarinic antagonist scopolamine (lower panel) did not fully generalize to CLZ at any of the tested doses, producing partial substitution at 2.0 mg/kg with 62.3% DLR. Response rates for scopolamine were significantly increased by the 0.25-and 4.0-mg/kg doses relative to VEH response rates (F 6,36 =17.654, p<0.0005) . Peripheral side effects were observed with the 4.0-mg/kg dose, including a noticeable increase in heart rate and respiration. Because of these systemic effects, higher scopolamine doses were not tested.
Quipazine generalization and coadministration with clozapine Figure 6 shows the results of generalization testing for the serotonergic agonist quipazine (upper panel) and for the coadministration of quipazine with the 2.5-mg/kg training dose of CLZ (lower panel). Quipazine did not substitute for CLZ, producing a maximum of 5.3% DLR at 16.0 mg/ kg. Quipazine, at 8.0 and 16.0 mg/kg, produced significant decreases in rates of responding (F 5,35 =18.355, p<0.0001). Coadministration of quipazine with 2.5 mg/kg CLZ (lower panel) produced a significant reduction in % DLR (as compared to CLZ alone) at the 8.0-and 16.0-mg/kg quipazine doses (F 4,28 =5.163, p<0.005) . Quipazine + CLZ produced a significant increase in response rates at the 4.0-mg/kg dose of quipazine (F 4,35 =3.987, p<0.01).
Discussion
The results of the present study demonstrated that CLZ readily established discriminative stimulus control in C57BL/6 mice at doses that did not significantly suppress response rates. These preliminary results in mice extend previous findings in rats (Goas and Boston 1978; Nielsen 1988; Porter et al. 2000; Prus et al. 2004) , pigeons (Hoenicke et al. 1992) , and squirrel monkeys characterizing the robust discriminative stimulus properties of CLZ.
The discriminative stimulus properties of CLZ have been extensively characterized in rats and appear to be mediated to a large extent through muscarinic antagonism (Nielsen 1988; Kelley and Porter 1997; Millan et al. 1999; Prus et al. 2004 ). Interestingly, Hoenicke et al. (1992) demonstrated that scopolamine failed to substitute in pigeons, while the 5-HT 2A/2C antagonist pizotifen fully substituted for CLZ. These findings suggest species differences in the relevance of muscarinic and serotonergic antagonism for CLZ's discriminative stimulus properties.
In the current study with C57BL/6 mice, the muscarinic antagonist scopolamine similarly failed to fully substitute for CLZ at the tested doses. Scopolamine, at 4.0 mg/kg (as well as at 0.25 mg/kg), produced a significant increase in response rates (see Fig. 5 , lower panel). In this study, response rate increases were only seen in compounds that possess muscarinic antagonism (i.e., CLZ, olanzapine, and scopolamine). Interestingly, a 4.0-mg/kg scopolamine dose also has been shown to increase locomotor activity in C57BL/6 mice (Bond 1988) . Higher scopolamine doses were not tested in the present study due to peripheral side effects; therefore, it is not known if a complete stimulus substitution for CLZ would have occurred at a higher dose. Other studies have shown reduced exploratory activity in C57BL/6 mice in this dose range (e.g., 2.0 mg/kg, Oliverio et al. 1973 ). As noted above, two doses of scopolamine in the present study (0.25 and 4.0 mg/kg) produced significant increases in response rates. Also, in rats trained to discriminate 5.0 mg/kg CLZ from vehicle, scopolamine produced full substitution for CLZ at 0.25 and 0.5 mg/kg (Kelley and Porter 1997) . Thus, the dose range of scopolamine tested in the present study was sufficient to be active in the brain, but these results failed to conclusively demonstrate a muscarinic receptor mechanism in the discriminative stimulus properties of CLZ in mice as has been shown in rats (with 5.0 mg/kg CLZ training dose; Kelley and Porter 1997; .
Furthermore, the atypical antipsychotics risperidone and ziprasidone, which have negligible muscarinic receptor activity (Schotte et al. 1996) , produced full CLZ substitution in the present study, and these observations further suggest that muscarinic antagonism may be less relevant to CLZ's stimulus properties in C57BL/6 mice. However, previous research from this lab has shown that risperidone, which has negligible muscarinic affinity, fully substitutes for a low, 1.25-mg/kg CLZ training dose (Porter et al. 2000) . In this regard, the discriminative stimulus properties of CLZ in the C57BL/6 mouse may be similar to a low CLZ training dose in the rat. The 2.5-mg/kg dose used in the present study with mice probably represents a high training dose as response rate suppression by 5.0 mg/kg CLZ precluded using that dose. Whether a lower training dose (i.e., less than 2.5 mg/kg CLZ) can be established with mice remains to be determined. However, full substitution by the muscarinic receptor antagonist trihexyphenidyl and a lack of substitution by the 5-HT 2A antagonist MDL100,907 for a 1.25-mg/kg CLZ training dose in rats (Prus et al. 2004) suggest that there may be important differences in the discriminative stimulus properties of CLZ in these two species.
Interestingly, in the present study, the 5-HT 2A/2B/2C receptor antagonist ritanserin fully substituted for CLZ; this is in contrast to previous studies with rats (Wiley and Porter 1992) . Additionally, coadministration of the serotonergic agonist quipazine partially blocked the discriminative cue of CLZ at doses that did not significantly disrupt rates of responding. In rats, it has been shown that the discriminative stimulus effects of quipazine are blocked by the 5-HT 2A antagonist pirenperone (Glennon et al. 1983) , that quipazine-ketanserin drug discrimination is mediated by 5-HT 2A receptors (Smith et al. 1995) , and that CLZ blocks the discriminative stimulus effects of quipazine (Friedman et al. 1984) . Thus, CLZ's discriminative stimulus properties in C57BL/6 mice may be more consistent with the 5-HT/ DA hypothesis of atypical antipsychotic action (Meltzer et al. 2003 ) than has been observed in the majority of drug discrimination studies with rats. This claim is further supported by the fact that olanzapine, risperidone, and ziprasidone, but not haloperidol or amphetamine, fully substituted for CLZ's discriminative stimulus in the present study. However, the conclusion that the CLZ cue in C57BL/6 mice is mediated by 5-HT 2 antagonism does not preclude the involvement of other receptor subtypes. Further studies are needed to fully characterize the discriminative stimulus properties of CLZ in C57BL/6 mice.
The continuing need for improved animal models in the search for novel drug treatments for schizophrenia is also being facilitated by the recent integration of molecular biological approaches, such as knockout and transgenic mice, in behavioral pharmacology (Gold 1996) . With regard to a knockout mouse, deletion of a target gene that codes for a neurotransmitter receptor is somewhat analogous to administering a pharmacological neurotransmitter receptor antagonist. This technique is particularly useful for a recently identified receptor subtype for which there is no existing selective ligand available. Molecular approaches such as gene-targeted knockout mutations, expression of an exogenous transgene, and the disruption of cellular expression of genes with antisense oligonucleotides are now being successfully used to study the genetic basis for the behavioral effects of drugs. Establishing CLZ drug discrimination in wild-type mice allows for the future use of molecular approaches such as knockout mice and transgenic mice in this assay. The use of CLZ drug discrimination procedures can provide valuable information about the similarities and differences among typical and atypical antipsychotic drugs. Whether the discriminative stimulus properties of antipsychotic drugs are related to their antipsychotic efficacy or adverse side effects, however, remains to be determined.
Although many preclinical models have differentiated between antipsychotic and other psychoactive drugs, only a few have differentiated between typical and atypical APDs, e.g., the paw test and the phencyclidine-induced disruption of prepulse inhibition of startle in rats (see review by Geyer and Ellenbroek 2003) . The development of a model capable of differentiating APDs based on serotonergic antagonism may have important implications for screening novel APDs. Meltzer et al. (2003) have suggested that serotonergic antagonism is a core component for an atypical APD receptor binding profile that has the potential to explain the lack of extrapyramidal motor side effects (EPS) and efficacy in treatment-resistant schizophrenia, as well as the ability to ameliorate the negative and cognitive symptoms associated with schizophrenia. The findings presented here suggest that the discriminative stimulus properties of CLZ in C57BL/6 mice are mediated by 5-HT 2 receptor antagonism and that these properties are similar to those elicited by the atypical APDs olanzapine, risperidone, and ziprasidone. Based on this evidence, the CLZ drug discrimination assay in C57BL/6 mice appears to be an effective model for identifying atypical antipsychotic drugs.
